Product Description
Mechanisms of Action: mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Bone Cancer|Soft Tissue Cancer|Sarcoma|Osteosarcoma
Phase 2: Prostate Cancer|Breast Cancer|Sarcoma|Non-Small-Cell Lung Cancer|Lymphoma|Myelofibrosis|Endometrial Cancer|Oncology Unspecified|Leiomyosarcoma|Osteosarcoma|Myeloid Leukemia|Myelodysplastic Syndrome|Liposarcoma
Phase 1: Gliosarcoma|Glioblastoma|Glioma|Lymphoma|Heart Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Endometrial Cancer|Oncology Unspecified|Breast Cancer|Multiple Myeloma|Sarcoma|Non-Small-Cell Lung Cancer|Peritoneal Cancer|Colorectal Cancer|Fallopian Tube Cancer|Prostate Cancer|Hepatic Insufficiency|Liver Failure|Primary Central Nervous System Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IoNIR-002 | N/A |
Not yet recruiting |
Coronary Stenosis|Coronary Artery Disease |
2026-09-01 |
|
CHAMPIONSHIP | N/A |
Recruiting |
Peripheral Arterial Disease |
2025-08-30 |
|
IonMAN | N/A |
Active, not recruiting |
Non-ST Elevated Myocardial Infarction|Coronary Stenosis|Coronary Disease |
2024-09-30 |
|
EluNIR-005 | N/A |
Completed |
Myocardial Ischemia|Coronary Stenosis |
2021-11-02 |